» Articles » PMID: 25209410

Bone Mineral Density After Childhood Cancer in 346 Long-term Adult Survivors of Childhood Cancer

Overview
Journal Osteoporos Int
Date 2014 Sep 12
PMID 25209410
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Summary: More than 45 % of long-term childhood cancer survivors (CCS) were diagnosed with osteopenia. Our data suggest that greater awareness for osteopenia is warranted in long-term CCS, especially in survivors who are older than 30 years, male, and underweight and were treated with cranial-spinal radiotherapy and/or steroids.

Introduction: Osteopenia is a potential complication of childhood cancer treatment, but the magnitude of this problem in survivors is unknown. We examined (determinants of) bone mineral density (BMD) status in long-term survivors of adult childhood cancer.

Methods: This retrospective single-centre cohort study included 346 subjects with the most common types of childhood cancer. Subjects had a median age at diagnosis of 7.0 years (range 0.1-16.8 years), a median age at follow-up of 24.5 years (range 18.0-47.6 years) and a median follow-up time of 16.7 years (range 5.6-39.9 years). Total body BMD (BMDTB) and BMD of the lumbar spine (BMDLS) were measured by dual X-ray absorptiometry. Osteopenia was defined as BMD standardized deviation score (SDS) below -1.

Results: Survivors had a lower BMDTB and BMDLS (mean SDS -0.55; p<0.001 and -0.30; p<0.001, respectively) as compared to healthy peers. Osteopenia (BMDTB and/or BMDLS) was present in 45% of the survivors. Multivariate logistic regression analyses identified age at diagnosis<12 years, age>30 years at follow-up, male gender, underweight at follow-up and treatment with cranial-spinal radiotherapy or prednisone as independent prognostic factors for osteopenia.

Conclusions: This large cohort of childhood cancer survivors identified osteopenia in 45% of CCS. This indicates that greater awareness is warranted, especially in survivors who are older than 30 years, male, have underweight and were treated with cranial-spinal radiotherapy and/or steroids.

Citing Articles

Bone health in childhood cancer survivors, is there really a problem? Pitfalls of assessment, calculating risk, and suggested surveillance and management for osteonecrosis and low and very low bone mineral density.

de Winter D, Neggers S, van den Heuvel-Eibrink M, van Atteveld J Endocr Connect. 2024; 13(12).

PMID: 39437150 PMC: 11623254. DOI: 10.1530/EC-24-0487.


Barriers, facilitators, and other factors associated with health behaviors in childhood, adolescent, and young adult cancer survivors: A systematic review.

de Beijer I, Bouwman E, Mulder R, Steensma P, Brown M, Araujo-Soares V Cancer Med. 2024; 13(12):e7361.

PMID: 39291862 PMC: 11192647. DOI: 10.1002/cam4.7361.


Bone health in childhood low-grade glioma: an understudied problem.

Van Roessel I, Gorter J, Bakker B, van den Heuvel-Eibrink M, Lequin M, van der Lugt J Endocr Connect. 2024; 13(10).

PMID: 39140359 PMC: 11466249. DOI: 10.1530/EC-24-0224.


Late effects of high-dose methotrexate in childhood cancer survivors: a Swiss single centre observational study.

Brunold K, Otth M, Scheinemann K Discov Oncol. 2024; 15(1):17.

PMID: 38270745 PMC: 10810765. DOI: 10.1007/s12672-024-00861-0.


Transition of young adults with metabolic bone diseases to adult care.

Ross J, Bowden M, Yu C, Diaz-Thomas A Front Endocrinol (Lausanne). 2023; 14:1137976.

PMID: 37008909 PMC: 10064010. DOI: 10.3389/fendo.2023.1137976.


References
1.
van Waas M, Neggers S, Pieters R, van den Heuvel-Eibrink M . Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. Ann Oncol. 2009; 21(5):1121-6. DOI: 10.1093/annonc/mdp414. View

2.
Boot A, de Ridder M, van der Sluis I, van Slobbe I, Krenning E, de Muinck Keizer-Schrama S . Peak bone mineral density, lean body mass and fractures. Bone. 2009; 46(2):336-41. DOI: 10.1016/j.bone.2009.10.003. View

3.
Lie Fong S, Lugtenburg P, Schipper I, Themmen A, de Jong F, Sonneveld P . Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod. 2008; 23(3):674-8. DOI: 10.1093/humrep/dem392. View

4.
Nysom K, Holm K, Michaelsen K, Hertz H, Jacobsen N, Muller J . Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant. 2000; 25(2):191-6. DOI: 10.1038/sj.bmt.1702131. View

5.
Lim J, Kim D, Lee J, Kim D, Cho J, Cho W . Young age at diagnosis, male sex, and decreased lean mass are risk factors of osteoporosis in long-term survivors of osteosarcoma. J Pediatr Hematol Oncol. 2012; 35(1):54-60. DOI: 10.1097/MPH.0b013e318275193b. View